Chimeric antigen receptor T-cell therapies: Optimising the dose (Q90349845)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:32175617%20AND%20SRC:MED&resulttype=core&format=json

13 April 2020

review article

1 reference

title

Chimeric antigen receptor T-cell therapies: Optimising the dose (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:32175617%20AND%20SRC:MED&resulttype=core&format=json

13 April 2020

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:32175617%20AND%20SRC:MED&resulttype=core&format=json

13 April 2020

author name string

Nathaniel Dasyam

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:32175617%20AND%20SRC:MED&resulttype=core&format=json

13 April 2020

Philip George

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:32175617%20AND%20SRC:MED&resulttype=core&format=json

13 April 2020

publication date

16 March 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:32175617%20AND%20SRC:MED&resulttype=core&format=json

British Journal of Clinical Pharmacology

13 April 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:32175617%20AND%20SRC:MED&resulttype=core&format=json

Preparation and characterization of a chimeric CD 19 monoclonal antibody

13 April 2020

cites work

1 reference

https://pubmed.ncbi.nlm.nih.gov/32175617

12 December 2020

Expression of immunoglobulin-T-cell receptor chimeric molecules as functional receptors with antibody-type specificity

1 reference

https://pubmed.ncbi.nlm.nih.gov/32175617

12 December 2020

Design and analysis of phase I clinical trials

1 reference

https://pubmed.ncbi.nlm.nih.gov/32175617

12 December 2020

Expression of chimeric receptor composed of immunoglobulin-derived V regions and T-cell receptor-derived C regions

1 reference

https://pubmed.ncbi.nlm.nih.gov/32175617

12 December 2020

Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary report

1 reference

https://pubmed.ncbi.nlm.nih.gov/32175617

12 December 2020

A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes

1 reference

https://pubmed.ncbi.nlm.nih.gov/32175617

12 December 2020

Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/32175617

12 December 2020

Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the gamma or zeta subunits of the immunoglobulin and T-cell receptors

1 reference

https://pubmed.ncbi.nlm.nih.gov/32175617

12 December 2020

Mechanisms of adoptive immunotherapy: improved methods for in vivo tracking of tumor-infiltrating lymphocytes and lymphokine-activated killer cells.

1 reference

https://pubmed.ncbi.nlm.nih.gov/32175617

12 December 2020

Chimeric receptors providing both primary and costimulatory signaling in T cells from a single gene product

1 reference

https://pubmed.ncbi.nlm.nih.gov/32175617

12 December 2020

Human T-lymphocyte cytotoxicity and proliferation directed by a single chimeric TCRζ /CD28 receptor

1 reference

https://pubmed.ncbi.nlm.nih.gov/32175617

12 December 2020

Activation of resting human primary T cells with chimeric receptors: costimulation from CD28, inducible costimulator, CD134, and CD137 in series with signals from the TCR zeta chain

1 reference

https://pubmed.ncbi.nlm.nih.gov/32175617

12 December 2020

IL-15 enhances the in vivo antitumor activity of tumor-reactive CD8+ T cells

1 reference

https://pubmed.ncbi.nlm.nih.gov/32175617

12 December 2020

Removal of homeostatic cytokine sinks by lymphodepletion enhances the efficacy of adoptively transferred tumor-specific CD8+ T cells

1 reference

https://pubmed.ncbi.nlm.nih.gov/32175617

12 December 2020

Glucocorticoids in T cell apoptosis and function.

1 reference

https://pubmed.ncbi.nlm.nih.gov/32175617

12 December 2020

CD28 costimulation provided through a CD19-specific chimeric antigen receptor enhances in vivo persistence and antitumor efficacy of adoptively transferred T cells.

1 reference

https://pubmed.ncbi.nlm.nih.gov/32175617

12 December 2020

IL-2 and IL-21 confer opposing differentiation programs to CD8+ T cells for adoptive immunotherapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/32175617

12 December 2020

Adoptive cell transfer: a clinical path to effective cancer immunotherapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/32175617

12 December 2020

Natural expression of the CD19 antigen impacts the long-term engraftment but not antitumor activity of CD19-specific engineered T cells.

1 reference

https://pubmed.ncbi.nlm.nih.gov/32175617

12 December 2020

Antitransgene rejection responses contribute to attenuated persistence of adoptively transferred CD20/CD19-specific chimeric antigen receptor redirected T cells in humans

1 reference

https://pubmed.ncbi.nlm.nih.gov/32175617

12 December 2020

Adoptive transfer of syngeneic T cells transduced with a chimeric antigen receptor that recognizes murine CD19 can eradicate lymphoma and normal B cells

1 reference

https://pubmed.ncbi.nlm.nih.gov/32175617

12 December 2020

Depicting adoptive immunotherapy for prostate cancer in an animal model with magnetic resonance imaging

1 reference

https://pubmed.ncbi.nlm.nih.gov/32175617

12 December 2020

Reprogramming CD19-specific T cells with IL-21 signaling can improve adoptive immunotherapy of B-lineage malignancies.

1 reference

https://pubmed.ncbi.nlm.nih.gov/32175617

12 December 2020

A transgene-encoded cell surface polypeptide for selection, in vivo tracking, and ablation of engineered cells

1 reference

https://pubmed.ncbi.nlm.nih.gov/32175617

12 December 2020

T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia

1 reference

https://pubmed.ncbi.nlm.nih.gov/32175617

12 December 2020

Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias

1 reference

https://pubmed.ncbi.nlm.nih.gov/32175617

12 December 2020

Protein L: a novel reagent for the detection of chimeric antigen receptor (CAR) expression by flow cytometry

1 reference

https://pubmed.ncbi.nlm.nih.gov/32175617

12 December 2020

A CD19/Fc fusion protein for detection of anti-CD19 chimeric antigen receptors.

1 reference

https://pubmed.ncbi.nlm.nih.gov/32175617

12 December 2020

Chimeric antigen receptor (CAR)-specific monoclonal antibody to detect CD19-specific T cells in clinical trials

1 reference

https://pubmed.ncbi.nlm.nih.gov/32175617

12 December 2020

Persistence and efficacy of second generation CAR T cell against the LeY antigen in acute myeloid leukemia

1 reference

https://pubmed.ncbi.nlm.nih.gov/32175617

12 December 2020

Blockade of PD-1 immunosuppression boosts CAR T-cell therapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/32175617

12 December 2020

Molecular pathways: interleukin-15 signaling in health and in cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/32175617

12 December 2020

1 reference

https://pubmed.ncbi.nlm.nih.gov/32175617

12 December 2020

Chimeric antigen receptor T cells for sustained remissions in leukemia

1 reference

https://pubmed.ncbi.nlm.nih.gov/32175617

12 December 2020

T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/32175617

12 December 2020

Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia

1 reference

https://pubmed.ncbi.nlm.nih.gov/32175617

12 December 2020

Chimeric antigen receptor-modified T cells derived from defined CD8+ and CD4+ subsets confer superior antitumor reactivity in vivo

1 reference

https://pubmed.ncbi.nlm.nih.gov/32175617

12 December 2020

Early memory phenotypes drive T cell proliferation in patients with pediatric malignancies

1 reference

https://pubmed.ncbi.nlm.nih.gov/32175617

12 December 2020

Distinct Signaling of Coreceptors Regulates Specific Metabolism Pathways and Impacts Memory Development in CAR T Cells

1 reference

https://pubmed.ncbi.nlm.nih.gov/32175617

12 December 2020

The novel anti-CD19 chimeric antigen receptors with humanized scFv (single-chain variable fragment) trigger leukemia cell killing

1 reference

https://pubmed.ncbi.nlm.nih.gov/32175617

12 December 2020

Identification of Predictive Biomarkers for Cytokine Release Syndrome after Chimeric Antigen Receptor T-cell Therapy for Acute Lymphoblastic Leukemia

1 reference

https://pubmed.ncbi.nlm.nih.gov/32175617

12 December 2020

CD19 CAR-T cells of defined CD4+:CD8+ composition in adult B cell ALL patients

1 reference

https://pubmed.ncbi.nlm.nih.gov/32175617

12 December 2020

CD19-Targeted chimeric antigen receptor-modified T-cell immunotherapy for B-cell malignancies

1 reference

https://pubmed.ncbi.nlm.nih.gov/32175617

12 December 2020

CD19-targeted CAR T-cell therapeutics for hematologic malignancies: interpreting clinical outcomes to date

1 reference

https://pubmed.ncbi.nlm.nih.gov/32175617

12 December 2020

Clinical manufacturing of CAR T cells: foundation of a promising therapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/32175617

12 December 2020

T cells expressing an anti-B-cell maturation antigen chimeric antigen receptor cause remissions of multiple myeloma

1 reference

https://pubmed.ncbi.nlm.nih.gov/32175617

12 December 2020

Immunotherapy of non-Hodgkin's lymphoma with a defined ratio of CD8+ and CD4+ CD19-specific chimeric antigen receptor-modified T cells

1 reference

https://pubmed.ncbi.nlm.nih.gov/32175617

12 December 2020

Toxicity and Efficacy Probability Interval Design for Phase I Adoptive Cell Therapy Dose-Finding Clinical Trials

1 reference

https://pubmed.ncbi.nlm.nih.gov/32175617

12 December 2020

Reporter gene imaging of targeted T cell immunotherapy in recurrent glioma.

1 reference

https://pubmed.ncbi.nlm.nih.gov/32175617

12 December 2020

Molecular remission of infant B-ALL after infusion of universal TALEN gene-edited CAR T cells

1 reference

https://pubmed.ncbi.nlm.nih.gov/32175617

12 December 2020

Lymphoma Remissions Caused by Anti-CD19 Chimeric Antigen Receptor T Cells Are Associated With High Serum Interleukin-15 Levels.

1 reference

https://pubmed.ncbi.nlm.nih.gov/32175617

12 December 2020

Current approaches to increase CAR T cell potency in solid tumors: targeting the tumor microenvironment

1 reference

https://pubmed.ncbi.nlm.nih.gov/32175617

12 December 2020

Intent-to-treat leukemia remission by CD19 CAR T cells of defined formulation and dose in children and young adults

1 reference

https://pubmed.ncbi.nlm.nih.gov/32175617

12 December 2020

Monocyte lineage-derived IL-6 does not affect chimeric antigen receptor T-cell function.

1 reference

https://pubmed.ncbi.nlm.nih.gov/32175617

12 December 2020

Equal opportunity CAR T cells

1 reference

https://pubmed.ncbi.nlm.nih.gov/32175617

12 December 2020

A single dose of peripherally infused EGFRvIII-directed CAR T cells mediates antigen loss and induces adaptive resistance in patients with recurrent glioblastoma.

1 reference

https://pubmed.ncbi.nlm.nih.gov/32175617

12 December 2020

Clinical development of CAR T cells-challenges and opportunities in translating innovative treatment concepts

1 reference

https://pubmed.ncbi.nlm.nih.gov/32175617

12 December 2020

Long-Duration Complete Remissions of Diffuse Large B Cell Lymphoma after Anti-CD19 Chimeric Antigen Receptor T Cell Therapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/32175617

12 December 2020

Function of Novel Anti-CD19 Chimeric Antigen Receptors with Human Variable Regions Is Affected by Hinge and Transmembrane Domains

1 reference

https://pubmed.ncbi.nlm.nih.gov/32175617

12 December 2020

Chimeric antigen receptor T-cell therapies for lymphoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/32175617

12 December 2020

Kinetics and biomarkers of severe cytokine release syndrome after CD19 chimeric antigen receptor-modified T-cell therapy.

1 reference

https://pubmed.ncbi.nlm.nih.gov/32175617

12 December 2020

Chimeric antigen receptor T-cell therapy - assessment and management of toxicities.

1 reference

https://pubmed.ncbi.nlm.nih.gov/32175617

12 December 2020

Cellular kinetics of CTL019 in relapsed/refractory B-cell acute lymphoblastic leukemia and chronic lymphocytic leukemia

1 reference

https://pubmed.ncbi.nlm.nih.gov/32175617

12 December 2020

Endothelial Activation and Blood-Brain Barrier Disruption in Neurotoxicity after Adoptive Immunotherapy with CD19 CAR-T Cells

1 reference

https://pubmed.ncbi.nlm.nih.gov/32175617

12 December 2020

Chimeric Antigen Receptor T Cells in Refractory B-Cell Lymphomas

1 reference

https://pubmed.ncbi.nlm.nih.gov/32175617

12 December 2020

Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma.

1 reference

https://pubmed.ncbi.nlm.nih.gov/32175617

12 December 2020

Incorporation of Immune Checkpoint Blockade into Chimeric Antigen Receptor T Cells (CAR-Ts): Combination or Built-In CAR-T.

1 reference

https://pubmed.ncbi.nlm.nih.gov/32175617

12 December 2020

Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia.

1 reference

https://pubmed.ncbi.nlm.nih.gov/32175617

12 December 2020

Long-Term Follow-up of CD19 CAR Therapy in Acute Lymphoblastic Leukemia

1 reference

https://pubmed.ncbi.nlm.nih.gov/32175617

12 December 2020

A guide to manufacturing CAR T cell therapies.

1 reference

https://pubmed.ncbi.nlm.nih.gov/32175617

12 December 2020

The Pharmacology of T Cell Therapies.

1 reference

https://pubmed.ncbi.nlm.nih.gov/32175617

12 December 2020

Extensions of the mTPI and TEQR designs to include non-monotone efficacy in addition to toxicity for optimal dose determination for early phase immunotherapy oncology trials.

1 reference

https://pubmed.ncbi.nlm.nih.gov/32175617

12 December 2020

Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia.

1 reference

https://pubmed.ncbi.nlm.nih.gov/32175617

12 December 2020

PET of Adoptively Transferred Chimeric Antigen Receptor T Cells with 89Zr-Oxine

1 reference

https://pubmed.ncbi.nlm.nih.gov/32175617

12 December 2020

Monocyte-derived IL-1 and IL-6 are differentially required for cytokine-release syndrome and neurotoxicity due to CAR T cells

1 reference

https://pubmed.ncbi.nlm.nih.gov/32175617

12 December 2020

T Cells Genetically Modified to Express an Anti-B-Cell Maturation Antigen Chimeric Antigen Receptor Cause Remissions of Poor-Prognosis Relapsed Multiple Myeloma

1 reference

https://pubmed.ncbi.nlm.nih.gov/32175617

12 December 2020

Chimeric Antigen Receptor T-Cells (CAR T-Cells) for Cancer Immunotherapy - Moving Target for Industry?

1 reference

https://pubmed.ncbi.nlm.nih.gov/32175617

12 December 2020

Human iPSC-Derived Natural Killer Cells Engineered with Chimeric Antigen Receptors Enhance Anti-tumor Activity

1 reference

https://pubmed.ncbi.nlm.nih.gov/32175617

12 December 2020

A Phase I/IIa Trial Using CD19-Targeted Third-Generation CAR T Cells for Lymphoma and Leukemia

1 reference

https://pubmed.ncbi.nlm.nih.gov/32175617

12 December 2020

Design considerations for early-phase clinical trials of immune-oncology agents

1 reference

https://pubmed.ncbi.nlm.nih.gov/32175617

12 December 2020

In Vivo Fate and Activity of Second- versus Third-Generation CD19-Specific CAR-T Cells in B Cell Non-Hodgkin's Lymphomas

1 reference

https://pubmed.ncbi.nlm.nih.gov/32175617

12 December 2020

Teaching an old dog new tricks: next-generation CAR T cells

1 reference

https://pubmed.ncbi.nlm.nih.gov/32175617

12 December 2020

Expanding the Therapeutic Window for CAR T Cell Therapy in Solid Tumors: The Knowns and Unknowns of CAR T Cell Biology

1 reference

https://pubmed.ncbi.nlm.nih.gov/32175617

12 December 2020

Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/32175617

12 December 2020

Chimeric antigen receptor (CAR) T therapies for the treatment of hematologic malignancies: clinical perspective and significance

1 reference

https://pubmed.ncbi.nlm.nih.gov/32175617

12 December 2020

Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/32175617

12 December 2020

An adaptive dose-finding design based on both safety and immunologic responses in cancer clinical trials

1 reference

https://pubmed.ncbi.nlm.nih.gov/32175617

12 December 2020

Recent advances in CAR T-cell toxicity: Mechanisms, manifestations and management

1 reference

https://pubmed.ncbi.nlm.nih.gov/32175617

12 December 2020

ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells

1 reference

https://pubmed.ncbi.nlm.nih.gov/32175617

12 December 2020

Engineering and Design of Chimeric Antigen Receptors

1 reference

https://pubmed.ncbi.nlm.nih.gov/32175617

12 December 2020

Manufacturing chimeric antigen receptor T cells: issues and challenges

1 reference

https://pubmed.ncbi.nlm.nih.gov/32175617

12 December 2020

Factors affecting lymphocyte collection efficiency for the manufacture of chimeric antigen receptor T cells in adults with B-cell malignancies

1 reference

https://pubmed.ncbi.nlm.nih.gov/32175617

12 December 2020

Chimeric antigen receptor T cell immunotherapy for multiple myeloma: A review of current data and potential clinical applications

1 reference

https://pubmed.ncbi.nlm.nih.gov/32175617

12 December 2020

CAR T-cells: costs, comparisons, and commentary

1 reference

https://pubmed.ncbi.nlm.nih.gov/32175617

12 December 2020

The response to lymphodepletion impacts PFS in patients with aggressive non-Hodgkin lymphoma treated with CD19 CAR T cells

1 reference

https://pubmed.ncbi.nlm.nih.gov/32175617

12 December 2020

Chimeric antigen receptor T cells for acute lymphoblastic leukemia

1 reference

https://pubmed.ncbi.nlm.nih.gov/32175617

12 December 2020

Target selection of CAR T cell therapy in accordance with the TME for solid tumors

1 reference

https://pubmed.ncbi.nlm.nih.gov/32175617

12 December 2020

Risks and Benefits of Chimeric Antigen Receptor T-Cell (CAR-T) Therapy in Cancer: A Systematic Review and Meta-Analysis

1 reference

https://pubmed.ncbi.nlm.nih.gov/32175617

12 December 2020

Chimeric antigen receptor T cell persistence and memory cell formation

1 reference

https://pubmed.ncbi.nlm.nih.gov/32175617

12 December 2020

Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma

1 reference

https://pubmed.ncbi.nlm.nih.gov/32175617

12 December 2020

Treatment of patients with relapsed or refractory CD19+ lymphoid disease with T lymphocytes transduced by RV-SFG.CD19.CD28.4-1BBzeta retroviral vector: a unicentre phase I/II clinical trial protocol.

1 reference

https://pubmed.ncbi.nlm.nih.gov/32175617

12 December 2020

Selecting costimulatory domains for chimeric antigen receptors: functional and clinical considerations

1 reference

https://pubmed.ncbi.nlm.nih.gov/32175617

12 December 2020

Cost Effectiveness of Chimeric Antigen Receptor T-Cell Therapy in Multiply Relapsed or Refractory Adult Large B-Cell Lymphoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/32175617

12 December 2020

Supercharging adoptive T cell therapy to overcome solid tumor-induced immunosuppression

1 reference

https://pubmed.ncbi.nlm.nih.gov/32175617

12 December 2020

Imaging CAR T cell therapy with PSMA-targeted positron emission tomography

1 reference

https://pubmed.ncbi.nlm.nih.gov/32175617

12 December 2020

Rapid tumor regression from PD-1 inhibition after anti-CD19 chimeric antigen receptor T-cell therapy in refractory diffuse large B-cell lymphoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/32175617

12 December 2020

NKT Cells Coexpressing a GD2-Specific Chimeric Antigen Receptor and IL15 Show Enhanced In Vivo Persistence and Antitumor Activity against Neuroblastoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/32175617

12 December 2020

2D (2 Dimensional) TEQR design for Determining the optimal Dose for safety and efficacy

1 reference

https://pubmed.ncbi.nlm.nih.gov/32175617

12 December 2020

Use of CAR-Transduced Natural Killer Cells in CD19-Positive Lymphoid Tumors

1 reference

https://pubmed.ncbi.nlm.nih.gov/32175617

12 December 2020

Approval of First CAR-Ts: Have we Solved all Hurdles for ATMPs?

1 reference

https://pubmed.ncbi.nlm.nih.gov/32175617

12 December 2020

Identifiers

DOI

10.1111/BCP.14281

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:32175617%20AND%20SRC:MED&resulttype=core&format=json

13 April 2020

1 reference